NICE to publish new guideline on treating chronic kidney disease with finerenone
Updated guidance on how finerenone can treat chronic kidney disease in people with type 2 diabetes will be published next week by the National Institute for Health and Care Excellence.
This new guideline will appraise the clinical and cost effectiveness of finerenone within its marketing authorisation for treating chronic kidney disease in people living with type 2 diabetes.
According to the National Institute for Health and Care Excellence (NICE), the expected publication date of the document is Thursday, March 23.
For more information on the guideline ‘Finerone for treating chronic kidney disease in people with type 2 diabetes’, click here.